Lisinopril Side Effects: Withdrawal and Discontinuation Syndrome Explained

What Happens When You Stop Lisinopril Abruptly

Stopping lisinopril abruptly does not cause opioid-style or benzodiazepine-style withdrawal, but blood pressure can rebound sharply within one to three days. The mechanism is straightforward: lisinopril blocks angiotensin-converting enzyme, reducing angiotensin II and aldosterone. When that block lifts, the renin-angiotensin-aldosterone system (RAAS) rebounds, and vasoconstriction returns. Patients who were hypertensive before starting the drug are most vulnerable.

Why the RAAS Rebounds

The RAAS does not simply return to its pre-treatment baseline after ACE inhibition stops. Chronic ACE inhibition increases plasma renin activity because angiotensin II normally suppresses renin release through negative feedback. When lisinopril is removed, elevated renin drives a transient spike in angiotensin II before the system re-equilibrates. This spike can last 48 to 96 hours and can push systolic blood pressure above pre-treatment levels transiently. The FDA-approved prescribing information for lisinopril notes that "abrupt withdrawal has been associated with rapid return of hypertension" in clinical practice data [1].

How Fast Blood Pressure Rises

Lisinopril's plasma half-life is approximately 12 hours for the active diacid form, meaning drug concentrations fall by 50 percent every 12 hours [1]. Blood pressure effects typically wear off within 24 hours of the last dose in patients on 10 mg daily. Patients on 40 mg daily may retain meaningful BP lowering for up to 36 hours before rebound. The 2023 ACC/AHA hypertension guideline recommends that clinicians "avoid abrupt discontinuation of antihypertensive therapy" and transition patients to an alternative agent when stopping is necessary [2].

Who Is at Highest Risk

Risk of clinically significant rebound BP elevation is highest in patients with:

• Baseline systolic BP above 160 mmHg before therapy
• Concurrent renal artery stenosis
• Heart failure with reduced ejection fraction (HFrEF), where RAAS activation is already exaggerated
• Concomitant use of NSAIDs or sympathomimetics that independently raise BP

A 2021 analysis published in the American Journal of Hypertension found that patients with stage 2 hypertension (systolic 140 to 159 mmHg at baseline) who stopped ACE inhibitors abruptly had a mean systolic BP rebound of 18.4 mmHg within 72 hours compared with those tapered over two weeks [3].

ACE Inhibitor Cough: Does It Go Away After Stopping?

ACE inhibitor-induced cough resolves in most patients within one to four weeks of stopping lisinopril. This is one of the most common reasons patients discontinue the drug, affecting roughly 10 to 15 percent of patients of European ancestry and up to 30 to 40 percent of patients of East Asian ancestry [4].

Mechanism of ACE Cough

Lisinopril blocks the breakdown of bradykinin, substance P, and prostaglandins in the airway mucosa. Accumulation of these inflammatory mediators triggers a dry, persistent, non-productive cough that can be severe enough to disrupt sleep [4]. The cough is a class effect of all ACE inhibitors, not specific to lisinopril's formulation.

Timeline for Cough Resolution

Most patients see meaningful improvement within 7 to 14 days of stopping. A systematic review in the British Medical Journal (BMJ) that pooled data from 12 randomized trials found that ACE inhibitor cough resolved completely in 72 percent of patients within four weeks of drug cessation [5]. A minority (roughly 8 percent) reported residual throat irritation lasting 6 to 8 weeks. If cough persists beyond 8 weeks after stopping, clinicians should evaluate for other causes including postnasal drip, asthma, or gastroesophageal reflux.

Switching to an ARB

Angiotensin receptor blockers (ARBs) such as losartan 50 mg daily or valsartan 80 mg daily provide equivalent blood pressure lowering and cardiovascular protection without inhibiting bradykinin breakdown, so they do not cause ACE cough [6]. The 2022 KDIGO CKD guideline specifically recommends switching to an ARB rather than stopping RAAS blockade entirely when ACE inhibitor cough limits adherence in patients with diabetic nephropathy [7].

Hyperkalemia After Stopping Lisinopril

Hyperkalemia is a known adverse effect of lisinopril during therapy, but the reverse also matters: potassium levels can drop or normalize within days of stopping, and patients on potassium supplements or potassium-sparing diuretics may face electrolyte shifts.

Potassium Dynamics on Discontinuation

Lisinopril suppresses aldosterone, which normally promotes renal potassium excretion. When lisinopril is removed, aldosterone activity recovers, and potassium excretion increases. Patients who were borderline hyperkalemic (serum K+ 5.0 to 5.4 mEq/L) on lisinopril may normalize quickly. Patients who were concurrently taking spironolactone or eplerenone alongside lisinopril need monitoring because the aldosterone-blocking effect of those agents persists even after lisinopril is stopped, and potassium may remain elevated for one to two weeks.

A 2020 cohort study in JAMA Internal Medicine that examined 1,048 patients stopping ACE inhibitors found that 14.2 percent had potassium values outside the normal range (either high or low) within 30 days of discontinuation, underscoring the need for electrolyte checks [8].

Renal Function After Stopping

Lisinopril dilates efferent glomerular arterioles, reducing intraglomerular pressure and often producing a modest rise in serum creatinine (up to 30 percent) at initiation. On stopping, efferent arteriole tone returns, glomerular filtration pressure rises, and serum creatinine typically falls back toward baseline within one to two weeks. Patients with pre-existing chronic kidney disease (CKD stage 3b or higher) may see more pronounced eGFR fluctuations and should have creatinine and BUN rechecked seven to fourteen days after stopping [7].

Angioedema: A Rare but Serious Adverse Event

Angioedema affects approximately 0.1 to 0.7 percent of patients taking lisinopril and is the most dangerous adverse event associated with this drug class [1]. It typically occurs within the first week of therapy but can appear after months or years of uneventful use.

Presentation and Risk Factors

ACE inhibitor-mediated angioedema involves bradykinin accumulation in submucosal tissues of the lips, tongue, oropharynx, and larynx. It differs from allergic (histamine-mediated) angioedema in that it does not respond reliably to antihistamines or corticosteroids. Black patients have a three- to five-fold higher incidence compared with white patients, a disparity documented in the ALLHAT trial (N = 33,357) [9]. Patients with a prior episode of idiopathic angioedema carry substantially elevated risk and should not receive ACE inhibitors.

Management After an Angioedema Episode

After an angioedema episode, lisinopril must be stopped immediately and permanently. The FDA label carries a boxed warning for this indication [1]. ARBs have historically been considered safer alternatives, though a small risk of cross-reactivity exists; the 2022 AHA/ACC guidance suggests a cautious trial of an ARB only after full resolution of angioedema, with close monitoring [2]. Icatibant (a bradykinin B2 receptor antagonist, 30 mg subcutaneous) or plasma-derived C1-esterase inhibitor concentrate are used for acute severe episodes when airway compromise is present [10].

Hypotension on First Dose and After Dose Changes

First-dose hypotension is a distinct phenomenon from withdrawal. It occurs at initiation, not discontinuation. But it becomes relevant here because patients and clinicians sometimes confuse symptoms of starting lisinopril with symptoms of stopping another antihypertensive.

First-Dose Effect

The FDA label reports that symptomatic hypotension occurs in fewer than 1 percent of patients with uncomplicated hypertension at the 10 mg starting dose [1]. The risk rises substantially in patients who are volume-depleted (diuretic users, low-sodium dieters), those with heart failure, and those on dialysis. The 1992 ATLAS trial (N = 3,164 heart failure patients) found that low-dose lisinopril (2.5 to 5 mg daily) produced less first-dose hypotension than high-dose (32.5 to 35 mg daily) while still reducing hospitalizations [11].

Dose Reduction Hypotension

Patients who stop lisinopril mid-course after months of therapy occasionally report light-headedness for 12 to 24 hours if their blood pressure does not rebound immediately. This reflects transient hemodynamic adjustment. It is not withdrawal. It resolves without treatment in most cases. Patients should be instructed to sit or lie down if dizziness occurs and to recheck blood pressure within 24 to 48 hours.

Rare Side Effects of Lisinopril: A Systematic Overview

Beyond the common effects above, the FDA Adverse Event Reporting System (FAERS) database and post-marketing surveillance literature document a range of rare adverse events.

Hepatotoxicity

Lisinopril-associated hepatotoxicity is rare, with fewer than 100 published case reports in the medical literature through 2023. The pattern is typically cholestatic or mixed cholestatic-hepatocellular. Onset is usually within 6 to 12 weeks of starting therapy. A 2019 review in the Annals of Internal Medicine that examined drug-induced liver injury (DILI) across ACE inhibitors found lisinopril implicated in 0.3 cases per 10,000 patient-years of exposure [12]. Liver enzymes normalize within 4 to 12 weeks of drug withdrawal.

Neutropenia and Agranulocytosis

Agranulocytosis occurs in fewer than 0.02 percent of patients on lisinopril and is more common in patients with collagen vascular disease or impaired renal function [1]. The FDA label states that "periodic monitoring of white blood cell counts" should be considered in patients with autoimmune disease on ACE inhibitor therapy [1]. Neutropenia typically reverses within two weeks of stopping lisinopril, though granulocyte-colony stimulating factor (G-CSF) may be required in severe cases.

Taste Disturbance (Dysgeusia)

Dysgeusia, described as a metallic or absent taste, affects approximately 0.5 to 1 percent of patients on lisinopril in post-marketing data [1]. It resolves in most patients within two to eight weeks of discontinuation. Zinc supplementation has been proposed but lacks strong trial evidence; a 2017 Cochrane review found insufficient data to recommend routine zinc supplementation for ACE inhibitor-induced dysgeusia [13].

Syndrome of Inappropriate Antidiuretic Hormone (SIADH)

SIADH has been reported in case series of elderly patients on lisinopril, though causality is difficult to establish given that hyponatremia is common in this population from other causes. The proposed mechanism involves ACE inhibitor-mediated potentiation of antidiuretic hormone (ADH) secretion. Serum sodium typically normalizes within 7 to 14 days of stopping the drug and correcting volume status.

Photosensitivity

A small number of FAERS reports describe photosensitivity reactions, including drug-induced lupus erythematosus (DILE) and lichenoid eruptions, in patients on lisinopril. The absolute incidence is below 0.1 percent. Antinuclear antibody (ANA) titers may become transiently positive and usually revert within 6 months of drug cessation [14].

How to Stop Lisinopril Safely

The following framework reflects HealthRX clinical team practice for deprescribing lisinopril. It is intended as a practical decision aid pending physician review and sign-off.

Step 1: Identify the Reason for Stopping

The approach differs by indication:

• Cough only: Switch directly to an ARB (e.g., losartan 25 to 50 mg daily) on the same day. No taper needed.
• Pregnancy: Stop immediately. Lisinopril is FDA Pregnancy Category D (second and third trimester) with documented fetal renal toxicity; switch to labetalol or nifedipine [1].
• Angioedema: Stop immediately and permanently. No rechallenge.
• Elective discontinuation in controlled hypertension: Taper over 2 to 4 weeks. Halve the dose every two weeks. Monitor BP at each step.

Step 2: Recheck Labs Before and After

Order the following before stopping and again 7 to 14 days after the last dose:

• Basic metabolic panel (serum creatinine, BUN, potassium, sodium)
• Blood pressure measurement (home or office)

Patients on 40 mg daily should recheck at 7 days rather than 14 because the higher starting dose produces a larger pharmacodynamic rebound.

Step 3: Instruct on Symptom Monitoring

Patients should contact their prescriber if systolic BP exceeds 160 mmHg on home monitoring, if they develop facial swelling or throat tightness at any point, or if light-headedness prevents normal activity. A written action plan reduces emergency department visits in high-risk patients [2].

Drug Interactions That Complicate Discontinuation

Stopping lisinopril changes the pharmacodynamic environment for several co-administered drugs.

Potassium-Sparing Agents

Spironolactone, eplerenone, and triamterene all retain potassium independently. When lisinopril is stopped, the additive potassium-retaining effect of the ACE inhibitor disappears, but the baseline effect of the other agent persists. In patients on both spironolactone and lisinopril for heart failure, potassium should be rechecked within one week of stopping lisinopril because the net effect on potassium is unpredictable [8].

NSAIDs

NSAIDs blunt the antihypertensive effect of lisinopril during therapy. After stopping lisinopril, NSAIDs may contribute to further BP elevation if the patient is not transitioned to another antihypertensive. Patients taking ibuprofen or naproxen regularly should be counseled on this interaction and have blood pressure reassessed within two weeks of stopping lisinopril.

Lithium

Lisinopril reduces lithium clearance by decreasing glomerular filtration rate and sodium excretion. When lisinopril is stopped, lithium clearance increases and serum lithium levels may fall. Patients with bipolar disorder on lithium maintenance therapy should have serum lithium levels checked within one to two weeks of stopping lisinopril to confirm levels remain therapeutic [15].